Acquired genetics, also referred to as somatic or onco-haematological genetics, is a discipline which requires a broad spectrum of specialised and innovative techniques.
Rapid technological developments in the field of genetics are leading to increasingly personalised care for patients with cancer.
The development of innovative molecular techniques, in particular high-throughput sequencing, now allows the simultaneous analysis of several dozen genes whose alterations have a major impact in onco-haematology. As a result, targeted panels are now available for the diagnostic, prognostic or theranostic management of myeloid haemopathies: myeloproliferative neoplasias (NMP), myelodysplastic syndromes (MDS), myelomonocytic leukaemia (LMMC) and acute myeloid leukaemia (AML).
We also offer several tests dedicated to chronic myelogenous leukaemia (CML) covering the entire natural progression of the disease: identification of the fusion transcript, monitoring of residual disease, search for mutations resistant to TKIs.
For the therapeutic management of certain solid tumours, cytogenetic (FISH) and molecular biology techniques are indispensable – therefore, the term “companion test” for targeted therapy is commonly used. For the past ten years, these molecular tests have been offered at Eurofins Biomnis in an isolated test format (e.g. EGFR, KRAS, NRAS or BRAF).
The laboratory now offers various gene panels dedicated to each organ (e.g. lung, colon, etc.) and analysed by high-throughput sequencing (NGS). This technique allows the molecular characterisation of tumours by simultaneously analysing several genes (from 3 to 24) involved in carcinogenesis.
